BioNTech (NASDAQ:BNTX) Trading Down 2.2% – Time to Sell?

BioNTech SE (NASDAQ:BNTX) shares fell 2.2% during mid-day trading on Wednesday . The company traded as low as $102.79 and last traded at $104.03. 215,127 shares traded hands during trading, a decline of 73% from the average session volume of 806,520 shares. The stock had previously closed at $106.40.

Analyst Ratings Changes

A number of equities analysts have recently commented on BNTX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, November 14th. Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $110.00 to $125.00 in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research note on Monday. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $138.79.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a 50-day simple moving average of $113.80 and a 200-day simple moving average of $97.56. The stock has a market cap of $25.94 billion, a PE ratio of -51.52 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.73 EPS. Sell-side analysts anticipate that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently modified their holdings of the company. Candriam S.C.A. increased its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after buying an additional 7,340 shares during the last quarter. Discovery Capital Management LLC CT purchased a new stake in shares of BioNTech in the 2nd quarter worth about $2,467,000. Finally, Deerfield Management Company L.P. Series C grew its stake in BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after acquiring an additional 24,426 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.